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Abstract 15 
The Type III secretion system (T3SS) is a protein export pathway that is widespread in 16 
Gram negative bacteria and delivers effector proteins directly into eukaryotic cells. At 17 
its core lies the injectisome, a sophisticated transmembrane secretion apparatus, and a 18 
complex network of specialized chaperones that target secretory proteins to the ante-19 
chamber of the injectisome. The assembly of the system, and the subsequent secretion 20 
of proteins through it, undergo fine-tuned, hierarchical regulation. Here, we present the 21 
current understanding of the injectisome assembly process, secretion hierarchy and the 22 
role of chaperones. We discuss these events in light of available structural and 23 
biochemical dissection and propose future directions essential in revealing mechanistic 24 
insight of this fascinating nanomachine. 25 
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From essential to specialized bacterial protein secretion systems 30 
Bacterial ribosomes synthesize up to 8,000 different proteins [1]. Almost half of 31 
these become embedded in membranes, are secreted to the cell wall or to the external 32 
milieu [1]–[4]. Many bacterial processes such as DNA replication, motility, transport, 33 
antibiotic resistance, scavenging of chemicals and pathogenesis depend on protein 34 
secretion. Many specialized protein export systems have evolved to tackle these 35 
processes [4]. Some of these systems allow proteins to be fully released extracellularly 36 
("secretion"), and sometimes even inside other host cells. The Type III secretion system 37 
(T3SS) is widespread in many Gram negative bacteria, including symbionts such as 38 
Rhizobium and pathogens that are responsible for a range of severe diseases such as 39 
plague (Yersinia pestis), typhoid fever (Salmonella typhi), gastroenteritis (Shigella 40 
flexneri) and infantile bacterial diarrhea (enteropathogenic Escherichia coli; EPEC) [5]. 41 
T3S is essential for the pathogenic potential of Gram negative bacteria by delivering 42 
essential "effectors", for example toxins and enzymes, into the eukaryotic cytoplasm. 43 
Remarkably, some of these effectors will travel across even more membranes inside the 44 
host; for example, into mitochondria [6]. Some bacteria have more than one T3SS and 45 
synthesize up to hundreds of copies of the 30-40 T3SS proteins [5] (Table 1). Synthesis 46 
and export of these molecules need to be co-ordinated so that the injectisome can be 47 
properly assembled and become functional; the proteins that build it and/or use it follow 48 
a strict hierarchy [7]. Thus, protein secretion through the T3SS is a highly regulated 49 
multi-step process, making it one of the most complex bacterial protein secretion 50 
systems known.  51 
 52 
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Form and parts of the injectisome 53 
The T3SS contains at its core the injectisome, a nanosyringe–like structure that 54 
transfers effectors into the host cell cytoplasm (Fig. 1A). Overall, injectisomes share 55 
high structural and genetic homology, and hence common ancestry [8], with the 56 
flagellar apparati (Fig. 1A)(specialized devices used for cell motility) and in parts with 57 
the F1F0 ATP synthases (Fig. 1B). Due to the conservation, data derived from either 58 
pathogenic or flagellar T3SSs from different bacteria are commonly combined to 59 
understand a unified mechanism of the secretion process. To unify the different protein 60 
and gene names and reduce confusion (for a selection see Table 1), common 61 
nomenclature rules have been proposed [9] including the Sct (Secretion and cellular 62 
translocation) moniker for the highly conserved genes. The Sct nomenclature has been 63 
exclusively adopted here.  64 
Analyses derived from X-ray crystallography, nuclear magnetic resonance (NMR), 65 
and cryo-electron microscopy (EM) visualization of several T3SS components [10]–66 
[13] has provided important structural insights in injectisome formation [8], [14], [15]. 67 
The injectisome spans two bacterial membranes and one eukaryotic membrane. It has 68 
three distinct parts (Fig. 1A): the extracellular segment; the basal body, which crosses 69 
both membranes of the Gram negative envelope; and the peripheral inner membrane 70 
cytoplasmic components [5]. The extracellular segment that bridges the bacterial outer 71 
membrane to the host plasma membrane comprises the needle that carries on one end 72 
either a tip or a filament and the translocator pore. The basal body is built of stacked 73 
toroids: an outer membrane ring (OM ring) extends to the periplasm and associates with 74 
the inner membrane one (IM ring). The basal body and the extracellular segment form 75 
a conduit through which effectors are transferred. The cytoplasmic components are the 76 
Portaliou et al T3S nanomachine  
 
 
5 
ATPase complex and the Cytoplasmic ring (C-ring) that are essential for protein 77 
secretion, presumably for protein sorting and unfolding of the secretory proteins, 78 
respectively (Fig.1A). Injectisome assembly and function are complicated processes 79 
that are under sophisticated regulation. 80 
How to build an injectisome: Sec- vs T3SS-dependent phases 81 
Assembly of the injectisome is precisely orchestrated in three discernible phases 82 
(Fig. 2). In the Phase I, the injectisome components enter the membrane and form the 83 
outer shell of the basal body. This process makes use of the Sec machinery, the essential 84 
system that the cell uses for 95% of its exported and membrane proteins (Fig. 2, I-III) 85 
[1], [2]. With the basal body frame in place, comes the T3SS-dependent phase during 86 
which the injectisome is completed with an internal connector of the basal body toroids, 87 
elongation of the needle and the formation of the translocator pore (Fig. 2, IV and V) 88 
[16], [17]. 89 
Sec-dependent formation of the Basal body shell 90 
The basal body comprises membrane-embedded ring-like structures that connect 91 
the inner and outer membrane by forming a continuous tubular conduit [14], [15]. The 92 
OM ring consists of the 12mer SctC, a member of the secretin family [16]. SctC has its 93 
N-terminal domain protruding deeply into the periplasm, forming a 16 nm-long funnel 94 
with a 7 nm-wide channel (Fig. 3) [18], [19]. For SctC oligomerization and stabilization 95 
in some cases the existence of the pilotin, a small lipoprotein, is essential [18], [20]. 96 
The MS (membrane and supramembrane) ring comprises an inner and outer toroid. 97 
The inner toroid is formed by a 24mer of the periplasm-facing lipoprotein SctJ; the 98 
outer toroid is formed by a 24mer of the single transmembrane domain (TM) protein 99 
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SctD, which "jackets" both the SctJ ring and the export apparatus (Fig. 3). The MS ring 100 
is stabilized through SctJ-SctD electrostatic interactions [15], [21]. The SctJ pore is 101 
negatively charged and might serve as an adaptor for the inner rod protein SctI to anchor 102 
[10], [22]. Upon MS ring assembly, SctD bridges the OM and the IM through its 103 
periplasmic domain (Fig. 3, DC) by interacting with the periplasmic domain of SctC 104 
and stabilizing the whole basal body structure [15], [22]–[25]. The N-terminal domain 105 
of SctD is flexible and resides in the cytoplasm (Fig. 3, DN), where it is thought to act 106 
as a dock for the C-ring [26], [27]. 107 
Five polytopic IM proteins (SctR, SctS, SctT and SctU, minor component; SctV, 108 
major component) form the "export apparatus"(Fig. 3) that is surrounded by the MS 109 
ring [7], [11]. SctR,S,T mainly consist of TMs with short linkers, whereas SctV and U 110 
also contain large, cytoplasmic C-terminal domains [11], [12], [28]. SctV assembles 111 
into a ring-like nonamer, with a 5 nm pore, via inter-subunit salt bridges [12]. Its C-112 
domain lies 6 nm distant from the membrane surface connected to the rest of SctV by 113 
a slender stem [12] (Fig. 3). Once embedded in the IM, the minor export apparatus is 114 
surrounded by the SctV ring [12], [29], [30].  115 
The hierarchy of OM, MS ring and export apparatus assembly is somewhat 116 
controversial. Once synthesized, their proteins are localized to the inner or translocated 117 
to the outer membrane. It has been proposed that the OM and MS rings are stably 118 
formed and attached to the membrane regardless of the existence of the export 119 
apparatus, and vice versa [14], [22](Fig. 2, I). Given the need for IM integration of the 120 
“export apparatus” proteins, presumably via Signal Recognition Particle-targeting and 121 
the SecYEG channel [17], the MS ring likely envelops a pre-assembled export 122 
apparatus.  123 
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Subsequently, either the MS ring is the first to be assembled in the IM, followed by 124 
periplasmic interlocking with SctC, or the SctC ring is formed in the OM and then the 125 
MS ring components SctD and J are assembled progressively and attached to the SctC 126 
ring using it as a building scaffold (Fig. 2, II-III) [7]. The two rings snap together during 127 
holo-machinery assembly, possibly bridged by electrostatic interactions between their 128 
periplasmic domains [7], [31]. 129 
T3SS-dependent phase of the injectisome 130 
Needle-filament formation and length regulation 131 
Once the basal body is assembled, it is used for further secretion of the injectisome 132 
components, SctF and SctI (early secretory substrates; hereafter "substrates"). SctF self-133 
oligomerizes to form the extracellular needle (Fig. 3). This needle is anchored to the 134 
basal body by the inner rod protein SctI (Fig. 3) and extends to the external milieu for 135 
lengths of 80nm-2µm [32]–[34]. SctI is localized inside the SctJ channel (Fig. 3) [35]–136 
[37] and appears to form a cylindrical conduit upon oligomerization [38], acting as a 137 
foundation for the growing needle [37], [39]. At the end of the needle either the tip 138 
protein or a filament is attached (Fig. 3). The tip protein usually forms a pentamer on 139 
the top of the needle [40] while the filament is a sheath-like structure that can be 140 
elongated up to 25nm [41], [42]. Tip or filament proteins share sequence similarity and 141 
hence common ancestry between different pathogenic T3SS and flagella [40], [43], 142 
[44]. Although filament and tip proteins are structurally distinct [40], [41], [43], [44], 143 
they appear to function similarly in T3S [44]. We therefore propose the common name 144 
SctA, separated in two classes; SctAf for filament and SctAt for tip proteins. (Table 1). 145 
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The needle or filament length varies between different bacteria and is dictated by 146 
the molecular ruler SctP. SctP is partially unfolded and "measures" the length of the 147 
developing needle, resulting in a needle-length that is proportional to the length of the 148 
extended SctP polypeptide in each organism [42], [45]. One model posits that SctP is 149 
sporadically secreted from the injectisome and somehow measures the needle from the 150 
outside (Fig. 4A, left) [42]. A second more prominent model, posits that SctP is 151 
anchored C-terminally on the SctU protein of the export apparatus [39], [46]–[48] and 152 
its N-terminus follows the developing needle anchored presumably to SctA [49], [50] 153 
(Fig. 4A, middle). According to a third model dissected in the flagellum, the increased 154 
concentration of the needle-analogue, flagellin protein, at the export apparatus 155 
promotes its secretion by preventing the interaction between the SctP and the SctU 156 
protein of the export apparatus [51], [52] (Fig. 4A, right). 157 
Formation of the translocator pore  158 
Once the needle is formed and the filament or tip is attached to it, the translocators 159 
(we propose here to call them SctB and E) are secreted and anchored on SctA. SctB and 160 
E (middle substrates) are mainly hydrophilic and are inserted in the host plasma 161 
membrane, whereupon they oligomerize to form the translocator pore [53], [54] (Fig. 162 
3). The translocator pore is a hetero-pentamer (4 SctE: 1 SctB) with an internal pore 163 
10nm-wide through which effectors (late substrates) will be injected in the host 164 
cytoplasm [53], [55]–[57] (Fig. 2,VI).  165 
C-ring and ATPase complex assembly and localization. 166 
The C-ring is made of SctQ, a peripheral membrane-associated protein essential for  167 
T3S. SctQ forms a circular 30nm-wide arrangement comprising 6 separated pods. The 168 
C-ring is docked on the MS ring on a peripheral IM pedestal formed by the N-terminal 169 
cytoplasmic domain of SctD, probably upon phosphorylation of SctQ (Fig. 3) [26], 170 
Portaliou et al T3S nanomachine  
 
 
9 
[27]. In contrast, the C-ring of the flagellar T3SS has a continuous cylindrical-and 171 
significantly wider (45nm diameter)-wall [58]–[60].  172 
The C-ring acts as a receptacle for the "ATPase complex," which comprises an 173 
ATPase held in place by two accessory components: the stator and the stalk [31]. The 174 
SctN ATPase (Fig. 1B; Fig. 3), homologous to the F1F0-ATPases (Fig. 1B) [11], [61], 175 
is a chemomechanical energy converter. SctN forms homo-hexameric rings with an 176 
internal diameter of 2.5-3 nm [61]–[66]. F1F0-ATPases consist of a membrane-177 
embedded F0 domain and a cytoplasm-exposed F1 domain. One end of the  central stalk 178 
of F1 attaches to the rotating c oligomer of F0, while the other inserts in the F1 ATPase 179 
hexamer composed of three α/β subunit pairs. An external stator (b2 and  subunits), is 180 
a second F0-F1 connector [67]–[69] that prevents the ATPase from rotating in vane when 181 
the central stalk rotates inside it (Fig. 1B). Similarly, SctN localizes stably to the 182 
membrane via the elongated α-helical SctL stator and the SctO stalk, both attached to 183 
the cytoplasmic domain of SctV [65], [70], [71]. SctL has an additional role; it acts as 184 
a chaperone-activity regulator of the ATPase in the cytoplasm, prevents SctN 185 
oligomerization and escorts it to the membrane [65], [72]. EM studies suggest that, once 186 
at the membrane, six SctL stators interact with the SctQ pods [8], [12], [60], [73], 187 
linking them to the ATPase, while also docking to SctV for membrane anchoring via 188 
its N terminus (Fig. 3) [71], [74], [75]. SctO stabilizes the SctN hexamer and stimulates 189 
its ATPase activity [65] and by analogy to the  stalk might insert partly inside the 190 
ATPase pore (Fig. 1B) [62], [65]. 191 
Although the T3SS can be divided in distinct structural parts, its assembly and 192 
protein secretion although consecutive, are multi-stepped and complex. Once the Sec-193 
dependent phase of assembly is completed, the T3SS-dependant phase is highly 194 
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regulated in all steps by different factors either protein components of the system and/or 195 
environmental ones.  196 
Regulation of secretion through the T3SS  197 
Almost all of the T3SS-related genes are clustered into operons found in specific 198 
loci on the bacterial chromosome or plasmids. Their transcription is co-ordinated and 199 
up-regulated under secretion-permissive conditions, through specialized sigma factors 200 
and transcriptional regulators [76], [77], resulting in the simultaneous presence of the 201 
majority of the system components in the cytoplasm [78]. Consequently, the T3SS 202 
needs mechanisms to prevent unspecific and untimely protein secretion and maintain 203 
the strict early-to-late substrate hierarchy of the process.  204 
Recognition-targeting 205 
Several T3SS secretory proteins contain non-cleavable signal sequences at their N 206 
termini (Fig. 5A) [79], but these sequences share little sequence or biophysical features 207 
and do not endorse the proteins for secretion hierarchy or for membrane targeting [80]. 208 
The export apparatus components SctU and V, the C-ring, the ATPase complex and the 209 
gatekeeper SctW are responsible for mediating different steps on the secretion pathway, 210 
such as the order of secretion, membrane targeting and export. However, [12], [15], 211 
[29]  little is known about the precise mechanism that is followed to segregate the 212 
secretory proteins in each step during secretion.  213 
Secretion switches 214 
Protein secretion through the injectisome occurs in consecutive steps and different 215 
switching mechanisms ensure the secretion hierarchy. 216 
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SctU has been proposed as the first regulatory switch. Once SctF is secreted and the 217 
needle is in place, the injectisome is ready to secrete all the other proteins. To signal 218 
this, the cytoplasmic domain of SctU undergoes auto-proteolysis, thus promoting 219 
conformational changes thought to alter the electrostatic surface of the export apparatus 220 
[81], [82].  221 
Two models attempt to explain this mechanism. According to the first one, the inner 222 
rod SctI (Fig. 4B, left) presumably interacts with SctU at the periplasmic phase of 223 
export apparatus, leading to its translocation into the basal body and association with 224 
the secretin SctC [83]. Once there, SctI somehow regulates the needle length and 225 
promotes SctU auto-proteolysis (Fig. 4B, left) [37], [39], [48], [83], [84]. The second 226 
model (Fig. 4B, right) proposes that once the needle or filament structure reaches the 227 
correct length, auto-proteolysis of SctU, on which the fully extended SctP is anchored, 228 
occurs [50], [52], [85]. Either way, cleaved SctU is thought to reduce the affinity of the 229 
apparatus for the early substrates resulting in the switch to middle substrate secretion 230 
[11], [81], [86]. 231 
Switch from middle to late substrate secretion is attributed to the gatekeeper SctW. 232 
In the absence of SctW, translocators (middle substrates) are not secreted, whereas 233 
effectors (late substrates) are over-secreted [80], [87]. Hence, SctW is needed for 234 
translocator secretion through an unknown mechanism. One proposal for this is that 235 
SctW is localized at the export apparatus and/or the C-ring [80], [88]. There, possibly 236 
selectively, it interacts with the translocators, sorts them and promotes their preferential 237 
secretion (Fig. 4C, left) [80], [88]–[90]. Otherwise, SctW possibly in a cytoplasmic 238 
phase, “captures” directly chaperone-effector complexes thereby preventing their 239 
access to the translocation pore (Fig. 4C, right), [42], [89], [91]. Translocators have 240 
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SctW-recognized sequences downstream of their export signals [80] (Fig. 5A). This 241 
lends strong support for an active role of SctW in translocator recognition and selection. 242 
Once the translocator pore in the host plasma membrane is formed, ion flow to the 243 
bacterial cytoplasm is thought to alter the local potential [92]. This alteration leads to 244 
either dissociation of SctW from the membrane (Fig. 4D, left) [93], [94] or its secretion 245 
from the injectisome (Fig. 4D, right) [95]. Detachment of SctW from the membrane 246 
presumably drives switching to late substrate secretion [92], [96], [97].  247 
Protein targeting to the membrane 248 
Apart from the switching-regulators, the major component of the export apparatus 249 
SctV acts as a regulatory or targeting receptor, presumably by interacting with 250 
chaperone-secretory protein complexes via its cytoplasmic nonameric ring [12], [14], 251 
[96], [98]. It has been proposed that conformational changes that occur upon SctU 252 
cleavage, SctW dissociation and/or the local potential changes at the membrane can 253 
regulate secretion steps by varying the binding affinities of the cytoplasmic domain of 254 
SctV for each chaperone-secretory protein complex. This mechanism was also 255 
proposed for the flagellar T3SS [14], [31], [99], [100]. 256 
Additionally, C-ring formation is believed to somehow serve in the sorting of 257 
exported proteins and transfer them to the ATPase and/or to SctV [101]. Interactions 258 
observed between SctQ and SctL may be important for regulating the hierarchy of 259 
secretion (hence also referred to as “sorting platform”) [27], [60], [73], [89]. However, 260 
the assembly and association of the C-ring-ATPase complex are highly dynamic and 261 
they easily detach from the membranes [27]. As a result they are not constitutively 262 
present at the injectisome entry point [8], [27]. This makes it less likely that they 263 
provide an essential contribution to sorting. Perhaps, C-ring formation is essential for 264 
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downstream events like stabilization and activation of the ATPase complex at the 265 
membrane. 266 
Nevertheless, the in vivo analyses, EM-studies, co-purification and protein-protein 267 
interaction studies to date cannot fully address the multi-leveled, complex mechanism 268 
mediating secretion regulation. For this, in vitro assays with purified components and 269 
a reconstituted injectisome would be required. 270 
Chaperone holdases are essential for protein secretion 271 
T3SS-secretory proteins depend on cytoplasmic chaperones for their efficient 272 
secretion [102], [103]. Chaperones form stable complexes with their secretory proteins, 273 
preventing the latter folding or aggregation, thus they display holdase activity. They are 274 
small, monomeric or dimeric and they share little sequence or structural similarities 275 
(Fig. 5B) [104]–[108]. Their genes are almost always located next to those of the 276 
secretory proteins [109]. Depending on the substrates they recognize, they fall into three 277 
classes: those that interact with early (Class II), middle (Class III) [102], [105], [110] 278 
and late secretory substrates (Class I). Class I chaperones can recognize specific either 279 
one or several homologous effectors (Class IA), or bind to different unrelated effectors 280 
(Class IB) (Fig. 5B, C) [102], [107]. 281 
 Class III chaperones usually contain three tandem tetratricopeptide repeats (TPRs), 282 
forming two anti-parallel α-helices, and imperfect amino-acid repeats, which are often 283 
involved in protein-protein contacts [110], [111], [66], [104], [106]. Some T3SS 284 
chaperones, such as CesAB of EPEC, prevent unspecific interactions by a self-285 
association mechanism that mimics the secretory-protein-bound-state [106] (Fig. 5D). 286 
T3SS chaperones can associate, either alone [107] or in complex with their cognate 287 
secretory substrates [66], with components of the injectisome. In the latter case the 288 
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targeting signals are conformational; that is, they are present in the chaperone structure 289 
but are only exposed upon allosteric changes brought about by secretory protein-290 
binding (Fig. 5D) [66]. Therefore, it has been proposed that chaperones may facilitate 291 
membrane targeting of secretory proteins and/or control the hierarchy of secretion, 292 
presumably by increasing the local concentrations of secretion substrates at the base of 293 
the injectisome or by competing for the same membrane receptor component [64]–[66], 294 
[98], [100], [107]. However, the molecular mechanism behind the targeting process 295 
remains unclear and the multiplicity of possible interactions complicates dissection in 296 
vivo. 297 
The ATPase complex and energy requirements for protein secretion 298 
The ATPase SctN is believed to catalyze disassembly of secretory protein-299 
chaperone complexes and/or secretory protein unfolding necessary for transport 300 
through the export apparatus [66], [112]. Not all secretory proteins are expected to 301 
acquire folded structures prior to export. SctN appears to interact with some secretory 302 
proteins and chaperones alone, or with their complexes [64], [66], [113]. Moreover, it 303 
was demonstrated that ATP hydrolysis is essential for secretory protein unfolding, 304 
which is necessary for transport [112]. It is expected that proteins must be in non-native 305 
states in order to cross the 2-3 nm pore of the inner channel of the export apparatus but 306 
the molecular basis of the mechanism remains unknown [66], [107], [112], [113]. 307 
Although ATP hydrolysis is important, it is not the only energy source for T3S 308 
[114]. In the absence of the ATPase or its stalk proteins, secretion is driven primarily 309 
by the proton motive force (PMF or H+), the electrochemical potential difference of 310 
protons across a membrane generated during electron transport in the bacterial plasma 311 
Portaliou et al T3S nanomachine  
 
 
15 
membrane [96], [114]–[116]. It was therefore proposed that the PMF drives protein 312 
transport across both bacterial membranes [74], [114], [115].  313 
Concluding remarks 314 
Type III protein secretion is essential for pathogenesis of many Gram negative 315 
bacteria. To co-ordinate more than 40 proteins for the formation of the injectisome, 316 
contact with the host and injection of effectors tight, sophisticated regulation is needed. 317 
Remarkable progress has been made towards understanding the structure and molecular 318 
mechanism of the injectisome. The view revealed is that of a complicated nanomachine 319 
that starts its assembly using the ubiquitous Sec system and completes its construction 320 
using itself as an export apparatus. As a finishing touch, the last components to be 321 
secreted provide a means of attachment of the injectisome to the host plasma membrane 322 
and a specialized translocator channel. Once the conduit that connects the two 323 
organisms is complete, secreted effector proteins cross through this channel into the 324 
eukaryotic host cytoplasm. Despite this progress, we are still missing detailed 325 
mechanistic understanding of the precise order of events, the mechanism of secretion, 326 
the pathway that secretory proteins take from their docking to transmembrane crossing, 327 
and the energetics of that pathway. Elucidating the molecular mechanisms that underlie 328 
T3S is essential and may allow us to potentially exploit T3S for specialized protein 329 
delivery [117], [118]. To address these issues it is of an essence to reconstitute the Type 330 
III protein-secretion pathway in vitro and obtain high-resolution structures of 331 
increasingly larger sub-assemblies of the device.  332 
 333 
334 
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Figure 1: Schematic comparison of the T3S injectisome, with a flagellum and the 762 
F1F0 ATPase 763 
A) Protein complexes were designed using Electron-microscopy (EM) structures as a 764 
matrix. The pathogenic T3SS is generated using :for the basal body: EMD accession 765 
number:1875, EMD accession number:5720, EMD accession number:5721 and EMD 766 
accession number:2669; the major export component: model from [12]; tip complex 767 
from EMD accession number:2805; needle from EMD accession number:1416. The  768 
flagellum is generated using: OM ring: EMD accession number:5310; Basal Body and 769 
C-ring from EMD accession number:1887; hook was generated using model from [119] 770 
and EMD accession number:1647; filament from EMD accession number:5007, [59], 771 
[119]–[121]. Homologous components are presented with the same color in the 772 
structures. The T3Ss comprises the extracellular segment, the basal body and the 773 
cytoplasmic components. 774 
B) Schematic comparison between the ATPase complex of T3SS (left) with the  F1F0 775 
ATPase synthase (right) is demonstrated due to high structural homology between them 776 
(F1F0 ATPase synthase model obtained from 10.2210/rcsb_pdb/mom_2005_12).   777 
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Figure 2: Schematic representation of Injectisome assembly (Sec and T3S phases) 778 
Schematic representation of injectisome assembly sub-divided in Sec- and T3S-779 
dependent phases. First the export apparatus needs to be localized to the inner 780 
membrane (Sec-dependent, phase I). Afterwards, the MS ring is formed by 781 
enveloping the export apparatus. Meanwhile, the OM ring has been localized in the 782 
outer membrane (Sec-dependent, phase II). The two ring-like-structures become 783 
bridged via intramolecular stabilizing interactions (Sec-dependent, phase III). During 784 
the T3S phase, the ATPase complex is transferred to the membrane and interacts with 785 
the C-ring and the export apparatus (T3SS-dependent, phase IV). The anchoring of 786 
the ATPase and C-ring to the membrane initiates the secretion of the early substrates 787 
(T3SS-dependent, phase V). Once the needle is attached to the host membrane via the 788 
translocator assembly that also forms the pore, the late substrates (i.e., various 789 
effectors) are secreted directly inside the eukaryotic cytoplasm (T3SS-dependent, 790 
phase VI). 791 
  792 
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Figure 3: Schematic representation, low and high resolution structures of 793 
injectisome subunits 794 
Cartoon representation of pathogenic T3SS using the common Sct nomenclature 795 
system (middle) [9]. The T3S injectisome comprises the translocators, tip 796 
complex/filament (olive green), the needle (dark yellow), the inner rod protein (yellow), 797 
the outer membrane ring (orange), the inner membrane ring (brown), the export 798 
apparatus (red), the cytoplasmic ring (dark green) and the ATPase complex (light 799 
green). Cross-sections of the injectisome are shown from the bottom to the top (left). A 800 
longitudinal cross-section of the right half of the injectisome is shown (right, grey). EM 801 
sections of the pathogenic T3SS structure generated using Chimera software. Available 802 
crystal structures of individual protein subunits or domains were manually placed inside 803 
the EM envelope for visualization and oriented as they are proposed to interact within 804 
the injectisome, using PyMOL Viewer. Where oligomerization is known to occur, only 805 
a single protomer is shown. EMD accession numbers: 1875, 2669, 1416 and 2805. PBD 806 
accession numbers: SctE: 3TUL, SctA: 4D3E, SctF 2X9C, SctC periplasmic domain 807 
3GR5, SctD (DC) periplasmic domain 4ALZ, SctD cytoplasmic domain (DN) 4A0E, 808 
SctJ 1YJ7, SctU cytoplasmic domain 3BZL, SctV cytoplasmic domain 4A5P, SctQ 809 
cytoplasmic domain and SctL N-terminal domain 4YXA, SctO 4MH6, SctN 2OBL, 810 
SctW 2VJ5. The EM section was and crystal structures. 811 
  812 
Portaliou et al T3S nanomachine  
 
 
38 
Figure 4: Proposed models for secretion regulation or switch 813 
A) Needle-length-Measuring Models. Left: SctP (magenta) is secreted and attached to 814 
the developing tip of the needle (olive green). Middle: SctP is C-terminally anchored 815 
on the SctU cytoplasmic domain (red), and follows needle growth with its N-terminus. 816 
Right: Increased concentration of needle protein subunits at the cytoplasmic domain of 817 
the export apparatus prevent the interaction between the SctP and SctU (cup-model) 818 
B) SctU (red) cleavage is promoted by conformational changes due to interactions 819 
between SctI (yellow) and SctF (olive green) (left) or due to the complete extension of 820 
SctP (magenta) (right). 821 
C) Left: SctW (magenta) shown bound to the membrane, presumably at the C-ring or 822 
the export apparatus. SctW may promote translocator protein secretion by interacting 823 
with chaperone-secretory protein complexes (blue and olive green, respectively). Right: 824 
SctW may prevent effector secretion by interacting with chaperone-effector complexes 825 
and blocking their membrane targeting (blue and orange). 826 
D) Influx of ions (“+” and “-“) from the host changes the local potential at the 827 
membrane, resulting either in the secretion of SctW (magenta) (left) or in its 828 
disengagement from the membrane and cytoplasmic release (right). These changes may 829 
lower the binding affinities of the export apparatus for middle substrates and increase 830 
the affinities for late substrate effectors. 831 
  832 
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Figure 5: Specialized chaperones of T3S, from structure to function 833 
A) General scheme of T3S-related recognition signals on secretory protein sequences. 834 
Within the N-terminal region lies a T3S-secretion signal, usually 20 amino acids long, 835 
that is poorly conserved among secretory proteins ([79], [122]). Downstream of the 836 
signal sequence lies the chaperone binding domain, usually from position ~50-100. This 837 
stretch is specifically recognized by the specialized chaperones and its length varies 838 
between different secretory proteins. Middle substrates (translocators) also possess a 839 
SctW-recognition signal that is located usually between the signal sequence and the 840 
chaperone binding domain (cross-hatched area). This signal somehow ensures their 841 
secretion prior to that of the effectors. 842 
B) Representative structures of different dimeric chaperones (green and light green for 843 
each protomer) of T3SS are shown following the protein secretion hierarchy (early to 844 
late substrates). Chaperone classes are indicated. PBD numbers from left to right: IpgC 845 
dimer (Shigella sp.) 3GYZ, YscE-YscG dimer (Yersinia sp.) 2P58, CesT dimer (EPEC) 846 
1K3E, Spa15 dimer (Shigella sp.) 2XGA. 847 
C) Representative structure of a chaperone-secretory protein complex (green and 848 
orange, respectively). According to the model a dimeric chaperone can bind one 849 
secretory protein. PDB accession number 2FM8 (InvB- SipA complex (Salmonella 850 
sp.)[123] . 851 
D) Chaperones can be auto-inhibited by self-dimerization. Here, CesAB of EPEC is 852 
auto-regulated using molecular mimicry of the secretory protein bound state. The 853 
CesAB-CesAB dimer (green and dark green represent each protomer) on the left as 854 
determined using in solution NMR. Crystal structure of CesAB in complex with 855 
secretory protein EspA. CesAB chaperone is shown ingreen and Secretory protein 856 
EspA in orange. Un-resolved structure in EspA is shown with orange-dashed line 857 
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(middle). Similar overall structures obtained in both cases. PDB accession numbers: 858 
2LHK (CesAB-CesAB) and 1XOU (CesAB-EspA). Upon binding to the secretory 859 
protein, a SctN targeting signal (red) is exposed on the surface of the chaperone due to 860 
conformational changes at the surface (right)861 
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Table 1: Unified nomenclature, localization and function of the T3S Injectisome and flagellum components 862 
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taExtracellular Components 
SctF Needle EscF PscF YscF MxiH PrgI SsaG CdsF BsaL HrpA HrpY HrpE / 
SctAt/f*
* 
Tip/ Filament EspAf PcrVt LcrVt IpaDt SipDt SseBt CT584 
or LcrVt 
BipDt /**** / / FliCf 
SctB*** Translocator EspB PopD YopD IpaC SipC SseD CopD1/2  BipC / XopA XopA / 
SctE*** Translocator EspD PopB YopB IpaB SipB SseC CopB1/2 BipB HrpK PopF1/PopF2 HrpF / 
Basal Body 
SctC OM ring EscC PscC YscC  MxiD  InvG  SsaC  CdsC  BsaO HrcC HrcC HrcC FlgI/FlgH 
/ Pilotin / ExsB YscW MxiM InvH  /  /  / / 
SctI Inner rod EscI PscI YscI MxiI  PrgJ SsaI / BsaK HrpB HrpJ HrpB2 FlgB/FlgC/FlgF
/FlgG 
SctD IM ring EscD PscD YscD MxiG PrgH SsaD CdsD BsaM HrpQ HrpW HrcD FliG 
SctJ IM ring EscJ PscJ YscJ MxiJ PrgK SsaJ CdsJ BsaJ HrcJ HrcJ HrcJ FliF 
SctR Export 
apparatus 
EscR PscR YscR Spa24 
(SpaP) 
InvL/Sp
aP 
SsaR CdsR  BsaW HrcR HrcR HrcR FliP 
SctS Export 
apparatus 
EscS PscS YscS Spa9 
(SpaQ) 
SpaQ  SsaS CdsS BsaX HrcS HrcS HrcS FliQ 
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SctT Export 
apparatus 
EscT PscT YscT  Spa29 
(SpaR) 
InvN/ 
SpaR  
SsaT CdsT BsaY HrcT HrcT  HrcT FliR 
SctU Export 
apparatus 
EscU PscU YscU Spa40 
(SpaS) 
SpaS  SsaU CdsU BsaZ HrcU HrcU HrcU FlhB  
SctV Export 
apparatus 
EscV PcrD  YscV MxiA  InvA  SsaV  CdsV  BsaQ HrcV HrcV HrcV FlhA 
Cytoplasmic Components 
SctQ  Cytoplasmic 
ring 
SepQ PscQ YscQ Spa33 SpaO SsaQ CdsQ BsaV HrcQA/
HrcQB 
HrcQ  HrcQA/
HrcQB 
FliM/ FliN 
SctL Stator EscL PscL YscL  MxiN OrgB SsaK CdsL OrgB HrpE HrpF HrcL FliH 
SctN ATPase  EscN PscN YscN Spa47  InvC  SsaN  CdsN BsaS HrcN HrcN HrcN FliI 
SctO Stalk EscO PscO YscO Spa13 InvI SsaO CdsO HrpD 
or BsaT 
HrpO HrpD HrpB7 FliJ 
SctP Molecular 
ruler 
EscP PscP YscP Spa32 InvJ SsaP CdsP BsaU HrpP HpaP HpaC FliK 
SctW Gate-keeper SepL PopN YopN/T
yeA 
MxiC InvE SsaL  CopN BsaP HrpJ HpaA HpaA / 
/ Regulatory 
compnent 
SepD / / / / SpiC / / / / / / 
SctK ATPase co-
factor 
/ PscK YscK MxiK  OrgA / / OrgA HrpD / / / 
Chaperones 
/ For early 
substrates 
EscE 
and 
EscG 
PscE 
and 
PscG 
YscE 
YscG 
   CdsE 
and 
CdsG 
     
/ For middle 
substrates 
CesA
B 
CesD 
CesD2 
PcrG 
PcrH 
LcrG 
SycD 
SycB 
IpgC 
IpgC 
SicA SseA 
SsaE 
LcrH     FliS 
FliT 
/ For late 
substrates 
 
CesT 
CesF 
SpcU 
Orf1 
SycE 
SycT 
SycH 
SycN 
IpgE 
Spa1 
IpgA 
SicP 
SigE 
InvB 
SigE 
SrcA 
SscB 
SycE BPSS1
51 
 
ShcA 
ShcM 
ShcF 
ShcV 
HpaB HpaB  
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YscB 
YsaK 
ShcO1 
ShcS1 
ShcS2 
* B. pseudomallei can also infect plants, 863 
 ** SctA proteins are 16% to 60% identical and highly similar between different pathogenic T3Ss and share 15% -30% homology with the flagellin component FliC. We 864 
propose to rename them collectively as "SctA". It must be noted that despite homologies they form morphophologically different structures. SctAf stands for filament 865 
proteins, and the SctAt for tip protein. 866 
*** SctB and SctE, proposed here as unified names for the translocators were not part of the original proposal [9]. 867 
****”/” indicates that there is no homologous protein known 868 
Note: Only some T3S systems, better characterized biochemically, from a small number of bacteria are included in this table. 869 
This table including active links and schematic diagrams of the injectisome can be accessed at the Sub-cellular Topology of E.coli Polypeptides Dadatbase (STEP 870 
db, http://stepdb.eu) 871 
 872 





